Try our Advanced Search for more refined results
Life Sciences - September, 2014
296 articles
- BD Stuck With $114M Antitrust Verdict After New Trial Denied
- Del. High Court Reverses Appriva Investors' $250M Ev3 Win
- Endo Settles 'Substantially All' AMS Vaginal Mesh Claims
- FDA Warns Valeant Over Wrinkle Jab Manufacturing Practice
- 9th Circ. Nixes Challenge To Calif. County's Drug Cleanup Law
- Medical Device Makers See Decline In FDA Discipline
- Novartis' FCA Suit Discovery Request Slammed By States
- Brazilian Vet Products Co. Aims To Fetch $148M In IPO
- SEC Accuses Two Of Illegal Tips On Ackman's Herbalife Bet
- And Now A Word From The Panel: ABCs Of JPML Practice
- ACA Database Shows Pharma Paid $3.5B To Docs, Hospitals
- $1.8B Alios Sale Marks Latham's 2nd Major Deal This Week
- AbbVie CEO Says New Rules Won't Derail $54B Shire Inversion
- Dealmakers Q&A: O'Melveny's Jennifer DePalma
- Drug-Device Applecart Upset Again
- Onyx Traders Can't Kill SEC's $4M Insider Trading Suit
- Products Cases To Watch As Supreme Court Term Kicks Off
- Jurors Can Hear About MDL In DePuy Hip Implant Bellwether
- Bankrupt Vitamin Maker Natrol Aims For Nov. Auction
- Kahn Swick Fights To Keep Abbott Fee Suit In State Court
- Medtronic Can't Shake Investors' Claims Of Tainted Studies
- Cos. Try To Nix More Experts In Nexium Pay-For-Delay Suit
- Atty Sues St. John's For Cut Of Patent Royalty Settlement
- Becton Dickinson Gets Catheter Patent Nixed In AIA Review
- The 4 Firms In-House Counsel Fear The Most
- Lipitor Plaintiffs Admit Pay-For-Delay Suit Doomed
- GlaxoSmithKline Settles Bias Claim By Male Sales Manager
- Takeda Expert Says Smoking Key In Actos Plaintiff's Cancer
- 3 Things To Know As Inversion Rules Muddle Medtronic Deal
- Fed. Circ. Upholds AllPure Win In Millipore Patent Suit
- Pressure Builds On FDA To Overhaul Guidance Process
- Good News For Originators Of Antibody Products
- Allergan Again Blasts Valeant Bid As Investors Urge Talks
- Are NY Practitioners, Pharmacies Ready For E-Prescribing?
- Brothers Still Can't Duck Chattem Insider Trading Verdict
- Chancery Allows Early Appeal In $255M Cornerstone Deal Suit
- Preemption Trend Favors Pharma In Generic Reglan Fight
- Pa. Superior Court Won't Rehear $10M Motrin Verdict
- Rare Arrest Warrant In WL Gore Chancery Case Sent National
- Deals Rumor Mill: AbbVie, ZF Friedrichshafen, T-Mobile
- Biotech Surge Continues With Coherus Filing For $86M IPO
- 1st Amendment Looms Large Over FDA's Twitter Rules
- DC Circ. Knocks FDA's Backtrack On Knee Implant Approval
- Dealmakers Q&A: Phillips Lytle's Asaf Hahami
- Dealmakers Q&A: Saul Ewing's David Antzis
- Investor Slams 'Hostile' Allergan Actions, Urges Deal Talks
- Standard Social Media Practices Are Risky For Big Pharma
- Drug Software Co. Loses Calif. Bid To Duck Warning Suit
- Abbott Labs Wins Nix Of RICO Claims In Humira, AndroGel Suit
- Judge Won't Exclude Experts In Nexium Pay-For-Delay Trial
- Judge Nixes Ohio Willow Patent For Inequitable Conduct
- Cephalon's Patent Experts Barred In FTC Pay-For-Delay Suit
- Genzyme Sues To Stop Generic Leukemia Drug Application
- FDA To Allow More Input Amid Informed Consent Uproar
- Enzo Pays $3.5M To End FCA Medicare Billing Suit
- Allergan Snubs Valeant's Olive Branch, Hints At Other Deal
- Dealmakers Q&A: WilmerHale's Stuart Falber
- Pfizer, AstraZeneca Deal Hopes Wilt After Inversion Rules
- FOIA Is Not Freedom For Plaintiffs To Drug Trade Secrets
- Dealmakers Q&A: Proskauer's Richard Zall
- Boston Scientific Owes $308M After Defibrillator Deal Trial
- FDA Gives Ground On Custom Medical Device Policies
- Abbott Buyout Target's Head Tipped Off Ex-Oriole, Feds Say
- Vertex, Gilead Want Poached-Worker Suit Axed After Deal
- NuVasive's 'Neurovision' Marks Axed As $30M Verdict Upheld
- FDA Eyes Cybersecurity Campaign On Medical Technology
- Reckitt Benckiser Takes Fight Over Suboxone Patent To NJ
- Ontario Gov't Pays $59M To Up Stake In Toronto Tower
- Actavis Seeks Access To NY AG's Files In Antitrust Case
- Nexium Buyers Fight Bid To Nix Experts In Pay-For-Delay Trial
- Chinese Pharma Co. Ducks Investor Suit Over Botched Sale
- Shire Inks $56.5M FCA Settlement Over Adderall Marketing
- Market Rumors: Naturhouse, Emaar Properties, Mercuria
- FDA Email Spying Suit Can't Skip Admin Review, Court Says
- Valeant Asks Allergan To Open Talks, Tone Down Buyout Fight
- Ex-Atty Who Committed Fen-Phen Fraud Gets 20 Years
- FDA Outlines Reforms Of Drug Safety Controls
- Kind Bar Maker, Vitamin Co. Settle Suit Over 'Kind' Marks
- Stiefel Escapes Bid For New Trial In $2M Securities Suit
- Accutane MDL Judge Tosses Roche Warning Label Suit
- Titan Of The Plaintiffs Bar: Daniel Berger
- Generics Lobby Threatens Suit Over FDA Warning Labels Plan
- GNC, USPlabs Settle Class Action Over Recalled Supplements
- Pa. Senate Committee Advances Medical Marijuana Bill
- Canadian Antitrust Chief Vows To Tackle Pay-For-Delay Deals
- Goldberg Segalla Adds Product Liability Attys To Philly Office
- Opportunities And Pitfalls In The Legal Cloud
- Invasion Of The Unannounced EU Notified Body Auditors
- Ackman Threatens To Sue Allergan Over Potential Salix Deal
- Dealmakers Q&A: Butler Snow's James Lawless
- Hospira Can't Kill Epinephrine False Ad Suit, Par Says
- Male Sex Enhancement Pill Maker Can't Escape False Ad Suit
- Valeant Wins Access To Allergan Docs In Insider Trading Row
- Covington Atty Seeks To Escape Subpoena In Nexium MDL
- Life Science Groups Chide CMS Over Sunshine Data Context
- FDA Twitter Rules Unconstitutional, Big Pharma Says
- Cohen Milstein Wrongly Handed Police Powers: Drugmakers
- Kelley Kronenberg Turns Focus To Medical Marijuana In Fla.
- Fleming Nolen Accuses 2 Firms Of Fen-Phen Deal Conspiracy
- CORRECTED: Par Pays $100M To Settle Suit Over Generic Heartburn Drug
- Red-Hot Life Sciences Sector A Skadden M&A Showcase
- Pfizer Pushes To Ax Rest Of Lipitor Pay-For-Delay Suit
- Merck Inks $17B Deal To Broaden Chemicals Business
- Auxilium Spurns $2.2B Endo Bid, Sticks To Acquisition
- Dealmakers Q&A: Epstein Becker's Kevin Ryan
- Purple Is The New Orange: A New Book On Biosimilars
- A General Counsel's Top 10 Billing Tips
- Full Fed. Circ. Won't Eye 'Mandate Rule' In Becton IP Case
- Biotechs Brave Market As Historic IPO Grabs Spotlight
- Merck, BMS Circling Deal With Cipla Over Sustiva Generic
- HHS Watchdog Warns Of Coupon Kickbacks In Part D
- FDA Chides Cipher Over Drug Ad's Superiority Claims
- Citing Lexmark, Drug Co. Says Bayer Couldn't Cancel Mark
- Allergan Defends Redactions In Valeant Insider Trading Suit
- Bill Exposes Drug Cos. To Suits For Abusing Safety Controls
- FCA Free Speech Defense Tested In DOJ-PhRMA Fight
- Criminal Division Wants In On FCA Whistleblower Complaints
- GSK Fined Record $489M For Bribery In China
- Dealmakers Q&A: Crowell & Moring's Bryan Brewer
- New, Final DEA Drug Disposal Rules Are Shady On Details
- Dealmakers Q&A: Nelson Mullins' Brian Moore
- ProQR Prices IPO At $102M Despite Other Biotech Flops
- Takeda Hid Actos Bladder Cancer Risks, Philly Jury Hears
- Testosterone Booster False-Ad Row Survives Dismissal Bid
- White House Gears Up To Combat Drug-Resistant Bacteria
- Medtronic Pays States To Settle Defibrillator FCA Claims
- FDA Panel Targets Testosterone Therapy Risks
- Eli Lilly Slams NY Cymbalta Suit As Possible MDL Looms
- Bayer To Spin Off $10B Polymer Biz In Public Listing
- TAA Case Is Study On Contractors' FCA Vulnerability
- Generics Need Sword, Shield For 'Exceptional' Patent Case
- Pa. High Court Nixes Teva Appeal In Reglan Preemption Fight
- DePuy Exec Defends Hip Implant Success Rate In Texas Trial
- DLA Piper Adds Ex-Pfizer Asia Ace To NY Office
- DOJ Urges FCA Attys To Aid Criminal Fraud Cases
- Valeant Slams Allergan Doc Redactions In Insider Trading Row
- Reckitt Says Suboxone 'Product-Hopping' Didn't Harm Buyers
- Avax Must Pay $5.8M For Breached Cancer Vaccine Contract
- Supplement Makers Pay $3M To End Joint Health False Ad Suit
- Catheter Maker Blasts Ivera's 'Intimidation' In IP Suit
- Judge Knocks Irell For Deposition Tactics In Patent Fight
- Mentor Investors' Appeal Over $1.1B J&J Sale Tossed
- Finnegan Withdraws As Counsel In Hepatitis C Drug IP Row
- Siga Technologies Blames Ch. 11 On Appeal Bond
- Auxilium Takes Poison Pill After $2.2B Endo Offer
- Activist Hedge Fund Wants DuPont Split Into 2 Cos.
- AIA Section 102 — Simplified
- AbbVie Investor Aims To Skunk $54B Shire Inversion
- FDA Clears Up 'Refuse To Receive' Rules For Generics
- Sullivan & Cromwell Reps Endo In $2.2B Auxilium Offer
- NY Antitrust Suit Tests Key Tactic Of Brand-Name Drugmakers
- CSC Unit Seeks $19M Over Botched US Vaccine Contract
- Fed. Circ. Nixes Boston Scientific Appeal In Stent IP Case
- Fla. Medical Marijuana Plan Faces Challenge From Nursery
- 'Male Performance' Supplement Is No Aphrodisiac, Suit Says
- Shire Sues CorePharma Over Plans For Generic Adderall
- Siga Files Ch. 11 After Losing Rival's Botched-Merger Suit
- Deal Makers Start Week With A Multibillion-Dollar Bang
- Novartis Sues Generics Maker Over Organ Rejection Drug
- Teva Again Tells High Court To Nix Claim Construction Rule
- Allergan Compromises With Valeant, Ackman On Meeting
- Post-Nautilus Most Indefinite Patent Challenges Fail
- NY AG Attacks Actavis' Plan To Force New Drug On Patients
- $73M Mesh Verdict Shows Email Evidence's Sway Over Jurors
- Ameritox's Drug-Test Cup Injunction Bid Falls Short
- Teva, AstraZeneca Want Expert Nixed From Nexium Trial
- NJ Mass Torts Relocated Out Of Atlantic County
- Fed. Circ. Won't Consider Sales Ban On Generic Latisse
- Payment Service Owner Cleared In Illegal Pharmacy Case
- Gilead, Indian Generic Cos. Reach Deals Over Hep C Drug
- ACE Won't Pay Amerisource's Attys' Fees After Pa. Appeal
- Alibaba To Overshadow Debuts Of 6 Health Care Cos.
- Ex-CEO Of Diagnostics Co. Alere Unveils $3.8B Buyout Plan
- Life Tech, Illumina Settle DNA Patent Row
- Walgreen Blasts 'Chutzpah' Of Attys' Fee Bid In Pfizer MDL
- Skadden Reps Danaher In $2.2B Nobel Biocare Purchase
- Takeaways For Generics After Octane And Highmark
- OPINION: Why Didn't McDonnell Plead Guilty?
- UK Floats Tighter Takeover Regs After Pfizer-AstraZeneca Bid
- Dealmakers Q&A: Ice Miller's Ed Braum
- Millennium Wins Bid to Reduce Damages in Ameritox Suit
- Pfizer Sheds Lipitor Buyers' Class Action In Antitrust MDL
- Glanbia Drops $153M For Isopure To Bulk Up Supplement Biz
- Chancery Won't Cancel Trial In Allergan Fight With Ackman
- Pfizer's Testosterone Drug Poses Heart Risks, Suit Says
- Kilpatrick Helped Client Steal Confidential IP, Suit Says
- OPINION: Pro Bono May Help Diversity Recruiting Efforts
- Twitter Not Off-Limits For Pharma, FDA Promo Chief Insists
- Bayer Dietary Supplement Ads Violate Court Order, US Says
- Suit Over Fatal Meningitis Outbreak Hits Health Providers
- Reed Smith Atty Widow Settles Subpoena Row With GSK
- J&J Unit, Bayer Want Xarelto Suit Shipped Out Of Philly
- Epstein Becker Green Adds Ex-Paul Hastings Health Care Ace
- 2nd Circ. Limits Monopolist Duty To Deal With Competitors
- Novartis Whistleblower Trims FCA Claims Against CVS
- Pharmacist In Meningitis Outbreak Case Pleads Not Guilty
- Suspect Arrested In Boston Scientific Atty's Shooting Death
- 11th Circ. Tells Fixodent Zinc Plaintiffs To Forget It
- Abbott Announces $3B Share Buyback, Quarterly Dividend
- J&J To Face Suit Over Allegedly Misleading Sunscreen Labels
- Ackman's Investor Support Tips Allergan Meeting Fight
- High-Profile Hostile Plays Reinforce Bright M&A Outlook
- FCA Whistleblowers Accuse Gilead Of Defective-Drug Fraud
- Nordion Says 11th Circ. Misapplied Test To Fla. Contract
- SEC Settles Heart-Monitoring Co.'s Stock-Inflation Case
- Lorillard Loses Appeal Of $45M Engle Verdict
- How Research Efficiency Impacts Law Firm Profitability
- What FTC Is Saying In 1st Post-Actavis Pay-For-Delay Case
- 5 Insights From Ford General Counsel David Leitch
- FDA Flouted 'Plain Meaning' Of Device Law, Judge Rules
- Insurer Off Hook For Defective Titanium Deal, NJ Court Says
- FDA Tells Compounder To Recall Contaminated Goods Again
- Cornerstone Directors Can't Escape Suit Over $255M Buyout
- Advanced Cell Settles SEC Claims Over CEO's Hidden Trading
- Fed. Claims Axes Health Co.'s Contract Over Supplier Status
- Regenerative Med Co. Says Ex-Employees Stole Trade Secrets
- NRDC Urges 2nd Circ. To Rehear Livestock Antibiotic Suit
- Lilly Opposes Creating MDL For Cymbalta 'Brain Zap' Suits
- JFTC Joins Regulatory Probes Of $13.4B Zimmer-Biomet Deal
- At The ITC, Even The Rulemaker Has To Follow The Rules
- Best Business Planning Practices For Lawyers
- 11th Circ. Won't Rehear Stiefel Appeal In $1.5M Share Fight
- PhRMA Fires Back At Feds In FCA Off-Label Suit
- 3rd Circ. Asked To Revive Genaera 'Fire Sale' Investor Row
- Lidoderm Buyers Fight Dismissal Bid In Pay-For-Delay Suit
- Chicago Fights Bid To DQ Cohen Milstein In Painkiller Suit
- Boston Sci Hit With $73M Verdict In 1st Pelvic Mesh Loss
- Class Suit Accuses Enzymotec Of Lying Before Its $70M IPO
- FDA Defends Lab Test Oversight Before Critical Lawmakers
- Goodwin Procter Snags Five-Atty IP Team From Kenyon
- 2nd Circ. Ruling May Spark More Lanham Act Cases
- Dealmakers Q&A: Sills Cummis' Ira Rosenberg
- When Inter Partes Review Meets Hatch-Waxman Patents
- State Claims Trimmed From AbbVie, Teva Pay-for-Delay MDL
- FTC Targets AbbVie, Teva In 1st New Pay-For-Delay Suit
- Aussie Court OKs Myriad Gene Patents, Knocks US High Court
- Lilly Funds Suit Against CMS Over Alzheimer's Test
- Allergan Can't Duck Class Action Over Cream Cancer Risks
- 4th Circ. Set Stage For Endless FCA Suits, Justices Told
- Pfizer, Purdue Prevail In Suit Over Settlement Records
- 23andMe Wants Hold On Coverage Suit Amid DNA Test Row
- Hospira Can't Block Generic Precedex, Judge Rules
- Alibaba Steals Spotlight As Fall US IPO Market Heats Up
- FDA Must Grant Depomed's Pain Drug Exclusivity, Judge Says
- Indian Watchdog Questions $3B Sun Pharma-Ranbaxy Deal
- Brand Battles: Samsung, Actavis, Hyundai
- Accentia Strikes $1.25M Deal To End Investors' Vaccine Suit
- Unions Aim To Bar Health Programs From Trade Deal Fights
- Antitrust, FCA Claims On Merck Mumps Vaccine To Advance
- Merck Ordered Into Mediation In Fosamax Litigation
- Boston Scientific Whistleblowers Can't Duck Counterclaims
- Costco, Apotex Sued Over Sales Of Imported Lipitor Generic
- Novartis Can't Escape FCA Drug Kickback Suit
- Hughes Hubbard Snags 2 Fried Frank Patent Partners In NY
- J&J's Ethicon Hit With $3.27M Verdict In Pelvic Mesh Trial
- Allergan OKs Shareholder Meeting In Win For Valeant, Ackman
- Biosimilar Patent Disputes: What Sandoz Appeal May Clarify
- Precedex Decision Will Impact FDA's Use Code System
- Dealmakers Q&A: Ropes & Gray's Matthew Richards
- 5 Insights From AT&T General Counsel Wayne Watts
- J&J, Ethicon Seek Early Win At Bellwether Pelvic Mesh Trial
- Loestrin Pay-For-Delay Case Can't Survive Actavis, Judge Says
- Document Storage Tips: Inside The Email Vault
- Forest Labs Sues Sigmapharm To Halt Generic Antipsychotic
- Hyman Phelps Says Baxter's HyQvia Needs Strict Labeling
- Daiichi Sankyo Targeted Worker In Retaliation, Suit Says
- Vaccine Investors Can't Exploit Tax Credit, UK Court Says
- PharMerica Can't Trim FCA Suit Over Painkiller Prescriptions
- Top NY Court Rejects Forest Lab Bid For Coverage From RSUI
- Ex-Va. Gov. McDonnell, Wife Found Guilty Of Corruption
- Pharmacist In Meningitis Outbreak Case Arrested At Airport
- Forest Asks 1st Circ. To End Lexapro Marketing Class Action
- Innovator Liability Finds Sweet Home In Ala.
- Deals Rumor Mill: Hospira, Pioneer, Bombardier
- Nautilus, Biosig Spar Over High Court Indefiniteness Ruling
- Hunt Continues For Boston Scientific Atty Shooter
- Smith & Nephew To Pay $8M To Settle FCA Suit With VA
- Clinic Owner Tied To MLB Doping To Plead Guilty In Oct.
- 4 Biotechs Set Terms As US IPO Market Braces For Surge
- Reed Smith Atty's Calls May Shed Light On Suicide, GSK Says
- FTC Promotes Attys Who Scrutinized ProMedica, Thermo Deals
- J&J, Boston Sci Can't Nix Pelvic Mesh Injury Claims En Masse
- Ranbaxy Fights Doc Bid In Nexium Pay-For-Delay Fight
- No Word From Pfizer, AstraZeneca As Deal Chatter Tapers
- The Glass Slipper: Searching For The FCA Case That Fits
- Pot Stock Puffery And Regulating An Illicit Industry
- Hi-Tech Execs Ordered To Jail For Contempt Of Recall Order
- Drug Cos. Call Chicago's Painkiller Marketing Suit Unwieldy
- Judge Favors Par In Novartis Alzheimer's Patch Patent Row
- Boehringer Sues Mylan To Block Generic Aggrenox
- Pfizer Ducks Zoloft False-Ad Claims In Calif.
- Allergan Must Face Suit Over Botox Labeling: 9th Circ.
- Vitamin Shoppe Sued Over Supplement False Labeling
- Allergan Hits Back After Valeant Stands By Business Model
- Dealmakers Q&A: Gray Plant's Mark Williamson
- Framing The Naming Debate For Biosimilars